On Monday, Nektar Therapeutics (NASDAQ: NKTR) opened lower -7.90% from the last session, before settling in for the closing price of $0.74. Price fluctuations for NKTR have ranged from $0.65 to $1.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -0.50%. Company’s average yearly earnings per share was noted -8.51% at the time writing. With a float of $179.37 million, this company’s outstanding shares have now reached $185.78 million.
Considering the fact that the conglomerate employs 61 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 68.82%, operating margin of -92.39%, and the pretax margin is -121.1%.
Nektar Therapeutics (NKTR) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Nektar Therapeutics is 3.62%, while institutional ownership is 69.48%. The most recent insider transaction that took place on Feb 19 ’25, was worth 10,403. In this transaction Chief R&D Officer of this company sold 10,300 shares at a rate of $1.01, taking the stock ownership to the 316,604 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Legal Officer sold 11,040 for $1.01, making the entire transaction worth $11,150. This insider now owns 324,292 shares in total.
Nektar Therapeutics (NKTR) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.68% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Check out the current performance indicators for Nektar Therapeutics (NKTR). In the past quarter, the stock posted a quick ratio of 4.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.58, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Compared to the last year’s volume of 2.09 million, its volume of 2.09 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 2.77%. Additionally, its Average True Range was 0.08.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 3.66%, which indicates a significant decrease from 3.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.85% in the past 14 days, which was lower than the 80.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8402, while its 200-day Moving Average is $1.1140. Nevertheless, the first resistance level for the watch stands at $0.7075 in the near term. At $0.7350, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.7545. If the price goes on to break the first support level at $0.6605, it is likely to go to the next support level at $0.6410. Now, if the price goes above the second support level, the third support stands at $0.6135.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
There are currently 186,104K shares outstanding in the company with a market cap of 126.55 million. Presently, the company’s annual sales total 98,430 K according to its annual income of -118,960 K. Last quarter, the company’s sales amounted to 29,180 K and its income totaled 7,260 K.
